Monica-Emilia Chirila

Dr. Monica-Emilia Chirila

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
IRIvica Ratosa
Ivica Ratosa
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
MSMateja Steinacher
Mateja Steinacher
EKElvisa Kozma
Elvisa Kozma
RVRadovan Vojtíšek
Radovan Vojtíšek
PPPhilip Poortmans
Philip Poortmans
We aimed to assess the prescription preference about hypofractionated radiation therapy (HFRT) for breast cancer (BC) patients amongst radiation oncologists (ROs) practicing in Europe and to identify restraints on HFRT utilisation. An online survey was circulated amongst ROs in Europe through personal, RO and BC societies' networks, from October 2019 to March 2020. The statistical analyses included descriptive statistics, chi-squared testing, and logistic regression analysis. We received 412 responses from 44 countries. HFRT was chosen as the preferred schedule for whole breast irradiation (WBI) by 54.7% and for WBI with regional nodes irradiation (RNI) by 28.7% of the responding ROs. In the case of postmastectomy RT with or without reconstruction, HFRT was preferred by 21.1% and 29.6%, respectively. Overall, 69.2% of the responding ROs selected at least one factor influencing the decision to utilise HFRT, the most frequent of which included age (51.4%), RNI (46.9%), internal mammary lymph nodes irradiation (39.7%), BC stage (33.5%) and implant-based breast reconstruction (31.6%). ROs working in academic centres (odds ratio, (OR), 1.7; 95% confidence interval, (CI); 1.1-2.6, p = 0.019), practicing in Western Europe (OR, 4.2; 95%CI; 2.7-6.6, p < 0.0005) and/or dedicating >50% of clinical time to BC patients (OR, 2.5; 95%CI; 1.5-4.2, p = 0.001) more likely preferred HFRT. Although HFRT is recognised as a new standard, its implementation in routine RT clinical practice across Europe varies for numerous reasons. Better dissemination of evidence-based recommendations is advised to improve the level of awareness about this clinical indication.

21 March 2022 in International Journal of Hyperthermia
Verified
Journal Article
Open access
JGJennifer Le Guévelou
Jennifer Le Guévelou
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
VAVérane Achard
Vérane Achard
PGPauline Guillemin
Pauline Guillemin
OLOrane Lorton
Orane Lorton
TZThomas Zilli
Thomas Zilli
Optimization of treatment strategies for prostate cancer patients treated with curative radiation therapy (RT) represents one of the major challenges for the radiation oncologist. Dose escalation or combination of RT with systemic therapies is used to improve tumor control in patients with unfavorable prostate cancer, at the risk of increasing rates and severity of treatment-related toxicities. Elevation of temperature to a supra-physiological level has been shown to both increase tumor oxygenation and reduce DNA repair capabilities. Thus, hyperthermia (HT) combined with RT represents a compelling treatment strategy to improve the therapeutic ratio in prostate cancer patients. The aim of the present systematic review is to report on preclinical and clinical evidence supporting the combination of HT and RT for prostate cancer, discussing future applications and developments of this combined treatment.

27 October 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
AZAlice Zamagni
Alice Zamagni
AMAngel Montero
Angel Montero
IMIngvil Mjaaland
Ingvil Mjaaland
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
RCRaquel Ciervide
Raquel Ciervide
PPPhilip M.P. Poortmans
Philip M.P. Poortmans
Preoperative radiation therapy (RT) for breast cancer is not a novel concept, though available data are insufficient to translate current knowledge into clinical practice. Nonetheless, potential advantages of this approach are emerging in multiple scenarios, incorporating increasing treatment personalization and technological improvements in RT. This paper aims to synthesize and summarize the literature on preoperative RT in distinct breast cancer treatment settings, providing perspectives based on existing evidence and gaps in knowledge. The ESTRO Breast subgroup proposal for elaborating perspectives on preoperative RT was approved by the ESTRO Guidelines Committee, and a panel of experts in the field was identified. Four working groups were created, focusing on the different clinical settings where preoperative RT has been investigated: patients with early-stage breast cancer at low risk of recurrence, patients with breast cancer at high risk of recurrence, and patients with an indication for mastectomy. The fourth group focused its search on cross cutting themes, such as preclinical and translational aspects, radiobiology, RT techniques and quality assurance. After a literature search including the identification of key points and gaps in the literature, the four working groups presented their findings and perspectives were formulated, discussed and approved by the panel. Overall, 27 phase I and phase II studies enrolling patients from the year 2000 onward were considered, collecting data such as RT dose and fractionation, clinical outcomes, and complications rates. The expert panel stated perspectives for the different clinical scenarios based on available evidence and current gaps in knowledge, to be addressed by future clinical research. Given the current lack of clinical data to support the development of formal guidelines, we present our perspectives, which can be useful for implementing new clinical trials and research projects, overcoming current limitations, and potentially generating high-quality practice-changing data, introducing preoperative RT in specific breast cancer treatment settings in the future.

19 February 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
FKFatjona Kraja
Fatjona Kraja
GMGustavo Nader Marta
Gustavo Nader Marta
WJWellington Furtado Pimenta Neves Junior
Wellington Furtado Pimenta Neves Junior
GAGustavo Viani de Arruda
Gustavo Viani de Arruda
IRIvica Ratosa
Ivica Ratosa
Advances in local and systemic therapies have improved the outcomes of patients with breast cancer (BC), leading to a possible increased risk for postoperative radiation therapy (RT) late adverse events. The most adequate technologies and dose constraints for organs at risk (OAR) in BC RT have yet to be defined. An online survey was distributed to radiation oncologists (ROs) practicing in Europe and Latin America including the Caribbean (LAC) through personal contacts, RO and BC professional groups' networks. Demographic data and clinical practice information were collected. The study included 585 responses from ROs practicing in 57 different countries. The most frequently contoured OAR by European and LAC participants were the whole heart (96.6 % and 97.7 %), the ipsilateral (84.3 % and 90.8 %), and contralateral lung (71.3 % and 77.4 %), whole lung (69.8 % and 72.9 %), and the contralateral breast (66.4 % and. 83.2 %). ESTRO guidelines were preferred in Europe (33.3 %) and the RTOG contouring guideline was the most popular in LAC (62.2 %), while some participants used both recommendations (13.2 % and 19.2 %). IMRT (68.6 % and 59.1 %) and VMAT (65.6 % and 60.2 %) were the preferred modalities used in heart sparing strategies, followed by deep inspiration breath-hold (DIBH) (54.8 % and 37.4 %) and partial breast irradiation (PBI) (41.6 % and 24.6 %). Only a small percentage of all ROs reported the dose-volume constraints for OAR used in routine clinical practice. A mean heart dose (Heart-Dmean) between 4 and 5 Gy was the most frequently reported parameter (17.2 % and 39.3 %). The delineation approaches and sparing techniques for OAR in BC RT vary between ROs worldwide. The low response rate to the dose constraints subset of queries reflects the uncertainty surrounding this topic and supports the need for detailed consensus recommendations in the clinical practice.

14 April 2025 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
PDF file
RZRenata Zahu
Renata Zahu
DUDaniela Urian
Daniela Urian
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
CTCristina Tiple
Cristina Tiple
MCMagdalena Chirila
Magdalena Chirila
GKGabriel Kacso
Gabriel Kacso
Background. Our objective was to evaluate the rate of reemployment after having curative radiotherapy for head and neck cancer and to identify the barriers of successful return to work in this patient population. Methods. The study was retrospective, cross-sectional, analytical and cohort type, it included 52 consecutive patients attending follow-up visits after curative radiotherapy for head and neck cancer at a single tertiary center. Participants completed a survey to assess demographics, tumor characteristics, lifestyle choices and quality of life questionnaires. We analyzed the rate of reemployment and the association with different parameters. Results. At the time of the survey, the successful return to work rate among head and neck cancer survivors was 55.8%. Most of the returners, 93%, started to work within 14 months from the time of the diagnosis. Educational level, work type and tumor stage were predictive for successful return to work. The main barriers for reemployment were physical symptoms such as fatigue, speech disorders and eating problems. Conclusions. Head and neck cancer survivors who manage to return to work have a better quality of life and global health status than those who could not return. The most vulnerable patients are those with lower education, doing manual work and with advanced stage cancer. Optimized radiotherapy planning to reduce radiation induced late effects in conjunction with coordinated rehabilitation programs are needed to facilitate head and neck cancer survivors’ reemployment.

24 May 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NNNam Nguyen
Nam Nguyen
Monica-Emilia ChirilaMonica-Emilia Chirila
Monica-Emilia Chirila
BPBrandi R. Page
Brandi R. Page
VVVincent Vinh-Hung
Vincent Vinh-Hung
OGOlena Gorobets
Olena Gorobets
AMAlessio G. Morganti
Alessio G. Morganti
The standard of care for non-metastatic renal cancer is surgical resection followed by adjuvant therapy for those at high risk for recurrences. However, for older patients, surgery may not be an option due to the high risk of complications which may result in death. In the past renal cancer was considered to be radio-resistant, and required a higher dose of radiation leading to excessive complications secondary to damage of the normal organs surrounding the cancer. Advances in radiotherapy technique such as stereotactic body radiotherapy (SBRT) has led to the delivery of a tumoricidal dose of radiation with minimal damage to the normal tissue. Excellent local control and survival have been reported for selective patients with small tumors following SBRT. However, for patients with poor prognostic factors such as large tumor size and aggressive histology, there was a higher rate of loco-regional recurrences and distant metastases. Those tumors frequently carry program death ligand 1 (PD-L1) which makes them an ideal target for immunotherapy with check point inhibitors (CPI). Given the synergy between radiotherapy and immunotherapy, we propose an algorithm combining CPI and SBRT for older patients with non-metastatic renal cancer who are not candidates for surgical resection or decline nephrectomy.